Grover P. Miller

Federal Grant PI High Impact

Professor

UAMS

Last publication 2025 Last refreshed 2026-05-22

faculty

Biochemistry & Molecular Biology, College of Medicine

30 h-index 109 pubs 2,748 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Grover P. Miller studies the biological significance of metabolic activation and clearance of molecules, with a focus on pharmacological and toxicological effects. His research group employs analytical and biochemical methods to identify and quantify small molecules, including drugs, pollutants, and food additives, during metabolism. These findings are then correlated with biological activity and in vivo outcomes, such as liver toxicity. Current projects investigate metabolic mechanisms, efficiencies, and fluxes for the activation and elimination of toxic molecules. Additionally, the group aims to identify metabolite biomarkers in humans and animal models to link in vitro findings to in vivo outcomes and explore their diagnostic, theragnostic, and prognostic potential. Computational models for drug bioactivation and clearance are also developed to contribute to the reduction of adverse drug events and improve drug safety for clinical use. Miller also seeks to translate novel analytical and diagnostic tools into practical, commercially viable applications. His work has expanded from detailed in vitro metabolic studies to metabolite profiling for translational research and the development of metabolism models.

Research Overview

My goals are to assess the biological significance of metabolic activation and clearance of molecules especially related to pharmacological and toxicological effects. In practice, my group leverages powerful analytical and biochemical tools to identify and quantitate small molecules including drugs, pollutants, and food additives during metabolism and correlate findings to biological activity and in vivo outcomes such as liver toxicity. Individual projects aim to (1) determine metabolic mechanisms, efficiencies, and fluxes for activation and elimination of toxic molecules, (2) identify metabolite biomarkers in humans and animal models for correlating in vitro findings to in vivo outcomes and leveraging their diagnostic, theragnostic, and prognostic potential, and (3) develop computational models for drug bioactivation and clearance contributing to adverse drug events to make drugs safer for clinical use. Moreover, I seek translation of novel analytical and diagnostic tools into practical, commercially viable tools. Over time, my research expanded from detailed in vitro metabolic studies to metabolite profiling for translational studies and development of models of metabolism, structure, and reactivity that were made possible through strong, interdisciplinary collaborations.

Metrics

h-index: 30
Publications: 109
Citations: 2,748

Selected Publications

The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications (2025)

4 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2023 year in review (2024)

DOI OpenAlex
Biotransformation research advances – 2022 year in review (2023)

5 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2022 year in review‡ (2023)

DOI OpenAlex
The Role of Cytochrome P450 3A4-Mediated Metabolism in Sorafenib and Lapatinib Hepatotoxicity (2023)

10 citations DOI OpenAlex
Editorial: Advancements in computational studies of drug toxicity (2023)

1 citation DOI OpenAlex
Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes (2022)

2 citations DOI OpenAlex
Bioactivation and reactivity research advances – 2021 year in review (2022)

2 citations DOI OpenAlex
Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin (2022)

1 citation DOI OpenAlex
CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs (2021)

7 citations DOI OpenAlex
Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort (2021)

42 citations DOI OpenAlex
4-Methyl-1,2,3-Triazoles as <i>N</i>-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity (2021)

33 citations DOI OpenAlex
Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors (2021)

3 citations DOI OpenAlex
Novel Bioactivation of Isoxazole‐containing Bromodomain and Extra Terminal Domain (BET) Inhibitors (2021)

DOI OpenAlex
Structural Variations among Marketed Diphenylamine NSAIDs Determine Preference and Efficiency for Four Possible Bioactivation Pathways (2021)

DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $76,500 total

NIH/National Institute on Drug Abuse Contact PI Sep 2025 - Aug 2027

Novel metabolic pathway for halogenated drugs of abuse

National Institute on Drug Abuse $76,500 R03

Research Interests

drug; metabolism; bioactivation; toxicity; in vitro; P450; modeling; Structure Activity Relationship, Quantitative; kinetics

Grants & Funding

RATE LIMITING STEPS IN CYTOCHROME P450 CATALYSIS NIH Principal Investigator
Structure-Function of UDP-Glucuronosyltransferases NIH Co-Investigator
No FP attached UAMS College of Medicine Principal Investigator
Investigating the Role of Protein-protein Interactions in the Oxidation of Fatty Acids by Cytochrome P4504A11 American Heart Association (Midwest Affiliate) Principal Investigator
Improving pediatric anticoagulant therapy through metabolic profiling of patients American Heart Association (SouthWest Affiliate) Principal Investigator
Novel metabolic pathway for halogenated drugs of abuse NIH/Nat. Inst. on Drug Abuse Principal Investigator
NIH COBRE Center for Protein Structure and Function NIH/Nat. Center for Research Resources Principal Investigator
Effects of Genetic Diversity on Carcinogen Metabolism NIH Co-Investigator